The National Institute for Health and Care Excellence (NICE) have published new or updated guidance for the month of May 2024. This month there are two guidelines that impact upon primary care.
The COVID-19 rapid guideline: managing COVID-19 guideline has been updated. It covers managing COVID-19 in babies, children, young people and adults in community and hospital settings. The update includes revised guidance and new recommendations on the use of anti-vial treatments for COVID-19.
The Atogepant for preventing migraine guideline has been published. It recommends this treatment as an option for preventing migraine in adults who have at least 4 migraine days per month, only if at least 3 preventive medicines have failed. It is further advised that treatment is stopped after 12 weeks if the frequency of migraine does not reduce by 50% in the case of episodic migraine or 30% in the case of chronic migraine. This treatment is reviewed in comparison to monoclonal antibody treatments and botulinum toxin type A and as such recommendation and treatment initiation would be supervised by a specialist.
Action: Clinicians should be aware of this month's new guidance and implement any necessary changes to practice.